Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL

Given intravenously on day 1 of every week for eight weeks (or 16 weeks)

Drug: Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks).